A new case report has just been published, and I've added it (and its electronic link) to the Disorder Resources section of this SCLS Community. Titled "High-dose intravenous immunoglobulins [IVIG]: A promising therapeutic approach for idiopathic systemic capillary leak syndrome," it tells the story of a 40-year-old woman with chronic SCLS treated in Berne, Switzerland, with IVIG after a prophylactic therapy with theophylline and terbutaline (T&T) was poorly tolerated and failed to decrease the frequency and severity of the attacks. Indeed, during the 5 years she was on T&T, the patient suffered from about 20 similar episodes of mild to moderate shock, often requiring hospital re-admission and supportive therapy. So far, 10 months of prophylactic therapy with IVIG (2gr/kg/month) have resulted in an impressive reduction of intensity and frequency of attacks, confirming the finding of other case studies likewise listed in the Disorder Resources section -- and the experience of a number of us in Canada, Europe and the United States. Your doctor should have access to this journal and thus to the article, but if he/she does not, let me know (at _aporzeca@american.edu_) and I'll send it to you. Every article like this makes it easier for someone else who is not yet on IVIG to obtain approval for this expensive but encouraging treatment.